Evaluate the Safety Profile of BGF MDI in Chinese Patients With COPD in Routine Clinical Practice

Inclusion Criteria: * Give their signed written informed consent to participate * Age: 18 and above * Chinese, Female or male * Patient with diagnosis of COPD as defined by clinicians * Subjects who have been prescribed and have planned to take at least one inhalation of Budesonide/Glycopyrrolate/Formoterol MDI based on physician's decision. Exclusion Criteria: Subjects who meet any of the following criteria will not be able to enter the study： * Subjects who are currently involved in any other interventional studies. * Drug Allergy: Subjects who have a history of hypersensitivity to formoterol or any other β2-agonists, budesonide or any other corticosteroid components, glycopyrronium or other muscarinic anticholinergics, or any component of the MDI. * Subjects who received investigational drug treatment within 30 days prior to Visit 1.